

Silencing of Mutant AR Co-activators as a Therapeutic Approach

Manuela Basso, Assistant Professor
*University of Trento, Centre for
Integrative Biology*




UNIVERSITY
OF TRENTO - Italy





Trento,
Italy



Basso's
Lab

Pennuto's
Lab

Italian Meeting with researchers and Scientists

November 2013, Padova



April 18th 2015, Trento

November 12th 2016, Milan

The fourth meeting is coming soon....



EUROPEAN NEURO MUSCULAR CENTRE


A new one coming up soon




March 27th-29th 2015


Naarden, The Netherlands

SBMA is caused by expansion of a polyglutamine tract in AR



AR post-translational modifications



 Polyglutamine tract

 Phosphorylation


 SUMOylation

 R methylation


 Acetylation

Palazzolo et al., 2007
Scaramuzzino et al., 2015
Montie et al., 2012
Chua et al., 2015


Arginine methylation is catalyzed by Protein Arginine Methyltransferases (PRMTs)



Arginine methylation and serine phosphorylation are mutually exclusive and both modulate AR function



Does PRMT6 modify toxicity *in vitro*?



Does PRMT6 modify toxicity *in vivo*?

AR

X

KD PRMT6





UAS-AR0Q
or
UAS-AR52Q




GMR-Gal4; DART8
silencing

PRMT6 modifies AR toxicity *in vivo*




AR is transcription factor



https://en.wikipedia.org/wiki/Androgen_receptor#/media/File:Human_androgen_receptor_and_androgen_binding.svg

PRMT6 specifically transactivates AR



AR transactivation by PRMT6 is enhanced by polyglutamine expansion

Is it possible to reduce the activity of PRMT6 and preserve the physiological functions of AR?

Hypothesis

SBMA pathogenesis is modified through arginine methylation of polyQ-expanded AR

1


Silence PRMT6 by an artificial microRNA to assess the rescue of polyQ-expanded AR *in vivo*

2

Silence PRMT6 by novel selective inhibitors to assess the rescue of polyQ-expanded AR



1a

Identify the best artificial miRNA for PRMT6




Debasmita Tripathy, postdoctoral

The artificial miRNA 13.1 silences PRMT6 of nearly 50%




The artificial miRNA 13.1 reduces AR function

Fold change (over negative control)




Fold change (over negative control)




1b

New transgenic mouse model





Mathilde Chivet
Pennuto's lab



Life span is reduced in mice overexpressing expanded AR




Weight body and strength are reduced in mice overexpressing expanded AR




Motor coordination is also reduced in mice overexpressing expanded AR



In progress:




2



Novel pharmacological inhibitors
MS023 and MS049

The novel inhibitors reduce AR-dependent transactivation



Where are we going?

1-Which are other AR coactivators?

2-Is it feasible to reduce the over-activation of AR to correct its transcriptional activity but maintain its physiological functions?

Acknowledgements

Maria Pennuto's Lab
University of Padova

Mathilde Chivet (Postdoctoral fellow)

Carlo Rinaldi's Lab

Oxford University


Giuseppe Ronzitti

Genethon, France






Alice Migazzi, PhD student



Mathi Chivet, postdoc





Debasmita Tripathy, postdoc









D







DAPI



ChAT



GFP



MERGED

